Cell Impact announces outcome in the exercise of warrants of series 2023/2024 TO2
Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) (“Cell Impact” or the “Company”) today announces the outcome of exercise of warrants of series 2023/2024 TO2, which were issued in connection with the Company’s rights issue of units in December 2023. In total, 104,821,096 warrants of series 2023/2024 TO2 were […]